- ISBN: 9781930624375 | 1930624379
- Cover: Paperback
- Copyright: 1/1/2003
What Is a CRA? | p. 13 |
The CRA--An Overview | p. 13 |
The CRA Personality | p. 15 |
CRA Tasks | p. 17 |
Career Preparation | p. 18 |
In the Future | p. 21 |
Your Value | p. 21 |
The History Behind the Regulations | p. 23 |
Regulation and Human Subject Protection Milestones | p. 24 |
Summary | p. 30 |
The Research Process | p. 32 |
Pre-clinical Research | p. 32 |
The IND (Investigational New Drug) Application | p. 37 |
Clinical Trials | p. 39 |
Summary | p. 45 |
Regulations and GCPs | p. 47 |
FDA Regulations for Clinical Trials | p. 48 |
ICH Guidelines for Good Clinical Practice | p. 48 |
FDA Guidelines and Information Sheets | p. 49 |
FDA Compliance Program Guidance Manuals | p. 49 |
NIH-Regulated Research | p. 50 |
FDA Bioresearch Monitoring Program (BIMO) | p. 50 |
Good Clinical Practice (GCP) | p. 51 |
Contacting the FDA | p. 51 |
Institutional Review Boards | p. 54 |
Types of IRBs | p. 55 |
IRB responsibilities | p. 56 |
IRB review of proposed research | p. 59 |
IRB Membership | p. 62 |
IRB Operations | p. 62 |
Conflict of Interest | p. 63 |
Informed Consent | p. 64 |
Monitoring Informed Consent | p. 65 |
Basic Elements of Consent | p. 66 |
Obtaining Informed Consent | p. 68 |
The Consent Process | p. 69 |
Exceptions from consent | p. 70 |
Conclusion | p. 73 |
Preparing for a Study | p. 74 |
Study Design | p. 74 |
Developing a Protocol | p. 82 |
Case Report Forms (CRFs) | p. 91 |
Clinical Investigators | p. 100 |
Investigators and Their Responsibilities | p. 100 |
Evaluating and Selecting Investigators | p. 104 |
Locating Potential Investigators | p. 106 |
Study Initiation | p. 114 |
Study Initiation Documents | p. 114 |
Financial Disclosure | p. 115 |
The Investigator Meeting | p. 117 |
Study Initiation Meetings | p. 125 |
Investigator Study Files | p. 128 |
Grants and Contracts | p. 130 |
Study Monitoring | p. 136 |
The Game Plan for Monitoring | p. 136 |
Preparing for a Monitoring Visit | p. 140 |
Site monitoring visits | p. 142 |
Confidentiality | p. 155 |
The End of the Visit | p. 156 |
Monitoring Visit Reports | p. 157 |
Conclusion | p. 158 |
Adverse Events and Safety Monitoring | p. 161 |
Regulations | p. 161 |
Adverse Events (AEs) on Marketed Products | p. 164 |
Adverse Events (AEs) in Clinical Trials | p. 165 |
Investigator Reporting Responsibilities | p. 168 |
Sponsor Responsibilities | p. 169 |
Differences Between Clinical Studies and Clinical Practice | p. 169 |
Common reporting problems | p. 172 |
Recruitment, Retention and Compliance | p. 174 |
Recruitment of Study Subjects | p. 174 |
Retention of Study Subjects | p. 185 |
Subject Compliance | p. 190 |
Study Closeout | p. 197 |
Reasons for study closeout | p. 197 |
Closeout procedures | p. 199 |
Audits | p. 203 |
Sponsor audits of investigative sites | p. 203 |
IRB audits of investigative sites | p. 206 |
FDA audits | p. 206 |
Errors, Misconduct and Fraud | p. 215 |
Definitions | p. 215 |
Errors | p. 216 |
Misconduct | p. 218 |
Fraud | p. 220 |
Conclusion | p. 226 |
Afterword | p. 227 |
Resources | p. 228 |
Hints and Tips | p. 233 |
Sample Forms, Checklists and Logs | p. 244 |
Job Descriptions and Academic Programs | p. 268 |
ICH-FDA Comparison | p. 276 |
Harmonized Tripartite Guidelines for Good Clinical Practice | p. 280 |
Code of Federal Regulations | p. 333 |
21 CRR 50 | p. 333 |
21 CFR 54 | p. 353 |
21 CFR 56 | p. 359 |
21 CFR 312 | p. 375 |
FDA Form 1572 | p. 439 |
About CenterWatch | p. 441 |
About the Authors | p. 447 |
Table of Contents provided by Rittenhouse. All Rights Reserved. |
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.
Digital License
You are licensing a digital product for a set duration. Durations are set forth in the product description, with "Lifetime" typically meaning five (5) years of online access and permanent download to a supported device. All licenses are non-transferable.
More details can be found here.